Cargando…

Mucormycosis in COVID-19 Patients: A Case-Control Study

(1) Background: During the second wave of COVID-19, India faced a rapid and sudden surge of not only COVID19-delta variant cases but also mucormycosis, making the infection even more fatal. We conducted a study to determine factors associated with the occurrence of mucormycosis in patients with COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandit, Awadh Kishor, Tangri, Poorvi, Misra, Shubham, Srivastava, Madakasira Vasantha Padma, Bhatnagar, Sushma, Thakar, Alok, Sikka, Kapil, Panda, Smriti, Vishnu, Venugopalan Y., Singh, Rajesh Kumar, Das, Animesh, Radhakrishnan, Divya M., Srivastava, Achal Kumar, Subramaniam, Rajeshwari, Trikha, Anjan, Agarwal, Ayush, Rajan, Roopa, Upadhyay, Vibhor, Parikipandla, Sathish, Singh, Anup, Kairo, Arvind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229175/
https://www.ncbi.nlm.nih.gov/pubmed/35744726
http://dx.doi.org/10.3390/microorganisms10061209
_version_ 1784734676377665536
author Pandit, Awadh Kishor
Tangri, Poorvi
Misra, Shubham
Srivastava, Madakasira Vasantha Padma
Bhatnagar, Sushma
Thakar, Alok
Sikka, Kapil
Panda, Smriti
Vishnu, Venugopalan Y.
Singh, Rajesh Kumar
Das, Animesh
Radhakrishnan, Divya M.
Srivastava, Achal Kumar
Subramaniam, Rajeshwari
Trikha, Anjan
Agarwal, Ayush
Rajan, Roopa
Upadhyay, Vibhor
Parikipandla, Sathish
Singh, Anup
Kairo, Arvind
author_facet Pandit, Awadh Kishor
Tangri, Poorvi
Misra, Shubham
Srivastava, Madakasira Vasantha Padma
Bhatnagar, Sushma
Thakar, Alok
Sikka, Kapil
Panda, Smriti
Vishnu, Venugopalan Y.
Singh, Rajesh Kumar
Das, Animesh
Radhakrishnan, Divya M.
Srivastava, Achal Kumar
Subramaniam, Rajeshwari
Trikha, Anjan
Agarwal, Ayush
Rajan, Roopa
Upadhyay, Vibhor
Parikipandla, Sathish
Singh, Anup
Kairo, Arvind
author_sort Pandit, Awadh Kishor
collection PubMed
description (1) Background: During the second wave of COVID-19, India faced a rapid and sudden surge of not only COVID19-delta variant cases but also mucormycosis, making the infection even more fatal. We conducted a study to determine factors associated with the occurrence of mucormycosis in patients with COVID-19. (2) Methods: This case–control study comprised 121 patients; 61 cases (mucormycosis with COVID-19) and 60 controls. Patients were included from April 10, 2021 onwards. Follow-up was conducted after about 90 days and health status was recorded based on the modified Rankin Scale (mRS). (3) Results: Mucormycosis with COVID-19 cases had a median (IQR) age of 49 (43–59) years with 65.6% males and were older (95% CI 1.015–1.075; p = 0.002) than in the control group with median (IQR) 38 (29–55.5) years and 66.6% males. Baseline raised serum creatinine (OR = 4.963; 95% CI 1.456–16.911; p = 0.010) and D-dimer (OR = 1.000; 95% CI 1.000–1.001; p = 0.028) were independently associated with the occurrence of mucormycosis in COVID-19 patients. Additionally, diabetes mellitus (OR = 26.919; 95% CI 1.666–434.892; p = 0.020) was associated with poor outcomes and increased mortality in patients with mucormycosis with COVID-19 as per the multivariable analysis. A total of 30/61 mucormycosis patients had intracranial involvement. (4) Conclusions: The study observed elevated levels of baseline raised creatinine and D-dimer in mucormycosis pa-tients with COVID-19 as compared to the control group. However, future studies may be conducted to establish this cause–effect relationship.
format Online
Article
Text
id pubmed-9229175
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92291752022-06-25 Mucormycosis in COVID-19 Patients: A Case-Control Study Pandit, Awadh Kishor Tangri, Poorvi Misra, Shubham Srivastava, Madakasira Vasantha Padma Bhatnagar, Sushma Thakar, Alok Sikka, Kapil Panda, Smriti Vishnu, Venugopalan Y. Singh, Rajesh Kumar Das, Animesh Radhakrishnan, Divya M. Srivastava, Achal Kumar Subramaniam, Rajeshwari Trikha, Anjan Agarwal, Ayush Rajan, Roopa Upadhyay, Vibhor Parikipandla, Sathish Singh, Anup Kairo, Arvind Microorganisms Article (1) Background: During the second wave of COVID-19, India faced a rapid and sudden surge of not only COVID19-delta variant cases but also mucormycosis, making the infection even more fatal. We conducted a study to determine factors associated with the occurrence of mucormycosis in patients with COVID-19. (2) Methods: This case–control study comprised 121 patients; 61 cases (mucormycosis with COVID-19) and 60 controls. Patients were included from April 10, 2021 onwards. Follow-up was conducted after about 90 days and health status was recorded based on the modified Rankin Scale (mRS). (3) Results: Mucormycosis with COVID-19 cases had a median (IQR) age of 49 (43–59) years with 65.6% males and were older (95% CI 1.015–1.075; p = 0.002) than in the control group with median (IQR) 38 (29–55.5) years and 66.6% males. Baseline raised serum creatinine (OR = 4.963; 95% CI 1.456–16.911; p = 0.010) and D-dimer (OR = 1.000; 95% CI 1.000–1.001; p = 0.028) were independently associated with the occurrence of mucormycosis in COVID-19 patients. Additionally, diabetes mellitus (OR = 26.919; 95% CI 1.666–434.892; p = 0.020) was associated with poor outcomes and increased mortality in patients with mucormycosis with COVID-19 as per the multivariable analysis. A total of 30/61 mucormycosis patients had intracranial involvement. (4) Conclusions: The study observed elevated levels of baseline raised creatinine and D-dimer in mucormycosis pa-tients with COVID-19 as compared to the control group. However, future studies may be conducted to establish this cause–effect relationship. MDPI 2022-06-13 /pmc/articles/PMC9229175/ /pubmed/35744726 http://dx.doi.org/10.3390/microorganisms10061209 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pandit, Awadh Kishor
Tangri, Poorvi
Misra, Shubham
Srivastava, Madakasira Vasantha Padma
Bhatnagar, Sushma
Thakar, Alok
Sikka, Kapil
Panda, Smriti
Vishnu, Venugopalan Y.
Singh, Rajesh Kumar
Das, Animesh
Radhakrishnan, Divya M.
Srivastava, Achal Kumar
Subramaniam, Rajeshwari
Trikha, Anjan
Agarwal, Ayush
Rajan, Roopa
Upadhyay, Vibhor
Parikipandla, Sathish
Singh, Anup
Kairo, Arvind
Mucormycosis in COVID-19 Patients: A Case-Control Study
title Mucormycosis in COVID-19 Patients: A Case-Control Study
title_full Mucormycosis in COVID-19 Patients: A Case-Control Study
title_fullStr Mucormycosis in COVID-19 Patients: A Case-Control Study
title_full_unstemmed Mucormycosis in COVID-19 Patients: A Case-Control Study
title_short Mucormycosis in COVID-19 Patients: A Case-Control Study
title_sort mucormycosis in covid-19 patients: a case-control study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229175/
https://www.ncbi.nlm.nih.gov/pubmed/35744726
http://dx.doi.org/10.3390/microorganisms10061209
work_keys_str_mv AT panditawadhkishor mucormycosisincovid19patientsacasecontrolstudy
AT tangripoorvi mucormycosisincovid19patientsacasecontrolstudy
AT misrashubham mucormycosisincovid19patientsacasecontrolstudy
AT srivastavamadakasiravasanthapadma mucormycosisincovid19patientsacasecontrolstudy
AT bhatnagarsushma mucormycosisincovid19patientsacasecontrolstudy
AT thakaralok mucormycosisincovid19patientsacasecontrolstudy
AT sikkakapil mucormycosisincovid19patientsacasecontrolstudy
AT pandasmriti mucormycosisincovid19patientsacasecontrolstudy
AT vishnuvenugopalany mucormycosisincovid19patientsacasecontrolstudy
AT singhrajeshkumar mucormycosisincovid19patientsacasecontrolstudy
AT dasanimesh mucormycosisincovid19patientsacasecontrolstudy
AT radhakrishnandivyam mucormycosisincovid19patientsacasecontrolstudy
AT srivastavaachalkumar mucormycosisincovid19patientsacasecontrolstudy
AT subramaniamrajeshwari mucormycosisincovid19patientsacasecontrolstudy
AT trikhaanjan mucormycosisincovid19patientsacasecontrolstudy
AT agarwalayush mucormycosisincovid19patientsacasecontrolstudy
AT rajanroopa mucormycosisincovid19patientsacasecontrolstudy
AT upadhyayvibhor mucormycosisincovid19patientsacasecontrolstudy
AT parikipandlasathish mucormycosisincovid19patientsacasecontrolstudy
AT singhanup mucormycosisincovid19patientsacasecontrolstudy
AT kairoarvind mucormycosisincovid19patientsacasecontrolstudy